- Home
- AMS vs IMNN Comparison
AMS vs IMNN Comparison
Compare AMS & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- IMNN
- Stock Information
- Founded
- AMS 1980
- IMNN 1982
- Country
- AMS United States
- IMNN United States
- Employees
- AMS N/A
- IMNN N/A
- Industry
- AMS Medical Specialities
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- IMNN Health Care
- Exchange
- AMS Nasdaq
- IMNN Nasdaq
- Market Cap
- AMS 13.7M
- IMNN 12.9M
- IPO Year
- AMS N/A
- IMNN 1985
- Fundamental
- Price
- AMS $2.07
- IMNN $3.77
- Analyst Decision
- AMS
- IMNN Buy
- Analyst Count
- AMS 0
- IMNN 2
- Target Price
- AMS N/A
- IMNN $182.61
- AVG Volume (30 Days)
- AMS 15.6K
- IMNN 56.4K
- Earning Date
- AMS 11-13-2025
- IMNN 11-13-2025
- Dividend Yield
- AMS N/A
- IMNN N/A
- EPS Growth
- AMS N/A
- IMNN N/A
- EPS
- AMS N/A
- IMNN N/A
- Revenue
- AMS $29,423,000.00
- IMNN N/A
- Revenue This Year
- AMS $5.06
- IMNN N/A
- Revenue Next Year
- AMS N/A
- IMNN N/A
- P/E Ratio
- AMS N/A
- IMNN N/A
- Revenue Growth
- AMS 17.84
- IMNN N/A
- 52 Week Low
- AMS $2.01
- IMNN $3.56
- 52 Week High
- AMS $3.59
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- AMS 39.59
- IMNN 35.44
- Support Level
- AMS $2.02
- IMNN $3.56
- Resistance Level
- AMS $2.31
- IMNN $4.38
- Average True Range (ATR)
- AMS 0.07
- IMNN 0.30
- MACD
- AMS 0.00
- IMNN 0.00
- Stochastic Oscillator
- AMS 7.69
- IMNN 21.95
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).